FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

11 results

azacitidine
(AZACITIDINE)
Eugia US LLC
Usage: Azacitidine for injection is indicated for treating adult patients with specific myelodysplastic syndrome subtypes, including refractory anemia, refractory anemia with ringed sideroblasts (with complications), refractory anemia with excess blasts, and chronic myelomonocytic leukemia. Pediatric use is not labeled due to marketing exclusivity.
azacitidine
(Azacitidine)
Cipla USA Inc.
Usage: Azacitidine for injection is indicated for adult patients with myelodysplastic syndromes (MDS), specifically subtypes such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia.
azacitidine
(Azacitidine)
Dr. Reddy's Laboratories Inc.
Usage: Azacitidine for injection is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), specifically refractory anemia, refractory anemia with ringed sideroblasts (with certain conditions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
decitabine
(Decitabine)
Novadoz Pharmaceuticals LLC
Usage: Decitabine for injection is indicated for treating adult patients with myelodysplastic syndromes (MDS), including all subtypes, both previously treated and untreated, as well as chronic myelomonocytic leukemia in various risk groups according to the International Prognostic Scoring System.
decitabine
(decitabine)
Gland Pharma Limited
Usage: Decitabine for Injection is indicated for adult patients with myelodysplastic syndromes (MDS), including all French-American-British subtypes and varying risk groups, regardless of prior treatment status.
grafapex
(treosulfan)
Medexus Pharma, Inc.
Usage: GRAFAPEX is indicated, in combination with fludarabine, as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients aged 1 year and older with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
lenalidomide
(Lenalidomide)
Biocon Pharma Inc.
Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.
lenalidomide
(lenalidomide)
Amneal Pharmaceuticals NY LLC
Usage: Lenalidomide is indicated for the treatment of adult patients with multiple myeloma in combination with dexamethasone and as maintenance therapy post-autologous hematopoietic stem cell transplantation. It also treats transfusion-dependent anemia in adults with low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q. Not recommended for CLL outside clinical trials.
lenalidomide
(lenalidomide)
Cipla USA Inc.
Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.
lenalidomide
(Lenalidomide)
Aurobindo Pharma Limited
Usage: Lenalidomide is indicated for treating multiple myeloma in adults, both as a combination therapy with dexamethasone and as maintenance therapy post-autologous stem cell transplantation. It is also used for transfusion-dependent anemia in adults with low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality.

Medications for Myelodysplastic Syndromes

azacitidine

azacitidine

azacitidine

decitabine

decitabine

grafapex

lenalidomide

lenalidomide

lenalidomide

lenalidomide